52023-48-0

Usage

Uses

Used in Pharmaceutical and Biochemical Research:
4-HYDROXY-2-MERCAPTOPTERIDINE is used as a precursor in the synthesis of various derivatives with potential pharmacological activities. Its unique structure allows for the development of new drugs and treatments that can address a range of health conditions.
Used in Antioxidant Studies:
Due to its chemical structure, 4-HYDROXY-2-MERCAPTOPTERIDINE exhibits antioxidant properties. It is used in research to understand its potential role in combating oxidative stress and related conditions, which can contribute to the development of novel therapeutic agents.
Used in Therapeutic Applications for Diabetes and Inflammation:
4-HYDROXY-2-MERCAPTOPTERIDINE has been studied for its potential therapeutic applications in conditions such as diabetes and inflammation. Its unique properties may offer new avenues for treatment, providing relief and improved outcomes for patients suffering from these conditions.

InChI:InChI=1/C6H4N4OS/c11-5-3-4(8-2-1-7-3)9-6(12)10-5/h1-2H,(H2,8,9,10,11,12)

Upstream product

• 112342-67-3 N-ethoxycarbonyl-N'-(3-benzyloxycarbonylpyrazinyl-2)-thiourea 
• 131543-46-9 Glyoxal 
• 1004-76-8 4,5-diamino-6-hydroxy-2-thiopyrimidine 
• 4363-38-6 ethylenedioxide 
• 59698-26-9 benzyl 3-aminopyrazine-2-carboxylate 

Downstream Products

• 14684-56-1 2-(ethylthio)-4-oxopteridine 
• 63012-75-9 2,3-dihydro-5H-thiazolo[2,3-b]pteridin-5-one 
• 63012-76-0 3,4-dihydro-2H,6H-[1,3]thiazino[2,3-b]pteridin-6-one 
• 1384266-20-9 [Au(P(C₆H₁₁)3)(C₄H₂N₂C₂HN₂OS)] 

Relevant academic research and scientific papers

Discovery of HIV-1 integrase inhibitors: Pharmacophore mapping, virtual screening, molecular docking, synthesis, and biological evaluation

HIV-1 integrase enzyme plays an important role in the life cycle of HIV and responsible for integration of virus into human genome. Here, both computational and synthetic approaches were used to design and synthesize newer HIV-1 integrase inhibitors. Pharmacophore mapping was performed on 20 chemically diverse molecules using DISCOtech, and refinement was carried out using GASP. Ten pharmacophore models were generated, and model 2, containing four features including two donor sites, one acceptor atom, and one hydrophobic region, was considered the best model as it has the highest fitness score. It was used as a query in NCI and Maybridge databases. Molecules having more than 99% Q fit value were used to design 30 molecules bearing pteridine ring and were docked on co-crystal structure of HIV-1 integrase enzyme. Among these, six molecules, showing good docking score compared with the reference standards, were synthesized by conventional as well as microwave-assisted methods. All compounds were characterized by physical and spectral data and evaluated for in vitro anti-HIV activity against the replication of HIV-1 (IIIB) in MT-4 cells. The used approach of molecular docking and anti-HIV activity data of designed molecules will provide significant insights to discover novel HIV-1 Integrase Inhibitors. Computer-aided drug design approaches like pharmacophore mapping, virtual screening, and molecular docking were used to design novel compounds bearing pteridine ring system. Designed compounds were synthesized by conventional and microwave-irradiated methods showing advantage of MWI method. All synthesized compounds were evaluated as HTV-1 integrase inhibitors and further explored to discover novel HIV-I integrase inhibitors.

Gold(I) complexes incorporating emissive mercapto-pteridine ligands: Syntheses, X-ray structure, luminescence and preliminary cytotoxic evaluation

The syntheses of six new mixed P/S-donor two-coordinate AuI complexes are described. The complexes incorporate a pteridinyl ligand coordinated through a thiolate donor, and an ancillary tertiary phosphane (PPh3 or PCy3). The mercapto-pteridine ligands (L 1-L3) differ in the nature of the substituents on the pteridine core. An X-ray crystal structure was obtained for one of the examples, [(L1)Au(PPh3)], revealing weak intermolecular interactions between two molecules of the complex: π-π contacts between aromatic rings appear to support an intermolecular Au-Au contact of approximately 3.05 A. All of the complexes are luminescent in solution, with emission arising from tuneable ligand-based excited states, and characterised as a perturbed fluorescence in nature. In this context, complexes of L3 displayed useful visible absorption and emission. Preliminary cytotoxicity assessments were conducted using the MTT assay, and the complexes each displayed impressive anti-proliferative activities (IC50 a given pteridine moiety, triphenylphosphane appeared to be the co-ligand of choice for enhancing biological activity. Copyright

Syntheses of novel heterocycles as anticancer agents

Several pteridine analogues 4-13, 23-26 have been synthesized and tested in vitro against three cancer cell lines, MCF7 (breast), NCI-H460 (lung) and SF-268 (CNS). All tested pteridines can serve as novel templates for the anticancer chemotherapy and can serve as new leads in cancer chemotherapy.

TRANSFORMATIONS OF 1,2,4-THIADIAZOLO/2,3-x/AZINES

Hydrolysis of 1,2,4-thiadiazolo/2,3-c/pyrimidine derivative 2 produced cyanoaminopyrimidine 4, while treatment of 1,2,4-thiadiazolo/2,3-b/pyridazine 5 with hydrazine hydrate gave thiourea derivative 7. 1,2,4-Thiadiazolo/2,3-a/pyridine 8 and 1,2,4-thiadiazolo/2,3-a/pyrazine 9 gave by alkaline hydrolysis the corresponding pyridopyrimidine 10 and pteridine 11, respectively.The compound 10 was converted with phenacyl bromide into 14 and further cyclized in PPA into pyrido/2,3-d/thiazolo/2,3-a/pyrimidine 15.Pyrazinylthiourea derivative 16 was cyclized in acidic solution into thiazolo/4,5-b/pyrazine 17, which was converted by hydrolysis and decarboxylation into amino derivative 20.This gave with ethyl acetoacetate pyrazino/2',3':4,5/thiazolo/3,2-a/pyrimidine 23. 1,2,4-Thiadiazoloazines 24 and N-ethoxycarbonyl-N'-azinylthioureas 25 were transformed with hydrogen peroxide into urea derivatives 26.